Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Krystal Biotech Inc (KRYS)

Krystal Biotech Inc (KRYS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,122,333
  • Shares Outstanding, K 28,761
  • Annual Sales, $ 50,700 K
  • Annual Income, $ 10,930 K
  • EBIT $ 27 M
  • EBITDA $ 31 M
  • 60-Month Beta 0.82
  • Price/Sales 100.89
  • Price/Cash Flow N/A
  • Price/Book 5.70

Options Overview Details

View History
  • Implied Volatility 42.11% ( +2.95%)
  • Historical Volatility 39.82%
  • IV Percentile 24%
  • IV Rank 14.38%
  • IV High 89.43% on 02/16/24
  • IV Low 34.16% on 11/14/24
  • Put/Call Vol Ratio 1.90
  • Today's Volume 223
  • Volume Avg (30-Day) 419
  • Put/Call OI Ratio 1.06
  • Today's Open Interest 8,792
  • Open Int (30-Day) 9,287

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 1.25
  • Number of Estimates 4
  • High Estimate 1.81
  • Low Estimate 0.96
  • Prior Year 0.30
  • Growth Rate Est. (year over year) +316.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
163.66 +8.82%
on 11/04/24
207.84 -14.31%
on 11/11/24
-1.09 (-0.61%)
since 10/18/24
3-Month
163.66 +8.82%
on 11/04/24
207.84 -14.31%
on 11/11/24
-20.92 (-10.51%)
since 08/20/24
52-Week
99.00 +79.90%
on 11/28/23
219.34 -18.80%
on 07/26/24
+73.32 (+69.98%)
since 11/20/23

Most Recent Stories

More News
Krystal Biotech to Present at Stifel 2024 Healthcare Conference

KRYS : 178.10 (+0.14%)
Krystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference

KRYS : 178.10 (+0.14%)
Krystal Biotech Announces Third Quarter 2024 Financial Results and Provides Business Updates

KRYS : 178.10 (+0.14%)
Krystal Biotech to Report Third Quarter 2024 Financial Results on November 4, 2024

KRYS : 178.10 (+0.14%)
Pacira's Exparel Receives Permanent New Product-Specific J-Code

Pacira BioSciences PCRX announced that the Centers for Medicare and Medicaid Services (CMS) has issued a permanent product-specific J-code (J0666) for its lead pain-management drug, Exparel (bupivacaine...

KRYS : 178.10 (+0.14%)
FULC : 2.99 (-0.66%)
ANIP : 55.10 (-1.06%)
PCRX : 17.03 (+1.79%)
Zevra Stock Surges Close to 70% in 3 Months: Here's Why

Zevra Therapeutics, Inc. ZVRA obtained FDA approval for arimoclomol capsules for the treatment of Niemann-Pick disease type C (NPC) in September. The drug will be marketed under the brand name Miplyffa.The...

ZVRA : 8.97 (unch)
KRYS : 178.10 (+0.14%)
FULC : 2.99 (-0.66%)
ANIP : 55.10 (-1.06%)
RARE's Wilson Disease Candidate Betters Standard Therapy in Study

Ultragenyx Pharmaceutical RARE reported positive updates from the Stage 1 cohorts of its phase I/II/III Cyprus2+ study evaluating UX701, an investigational AAV9 gene therapy, to treat Wilson disease. Stage...

KRYS : 178.10 (+0.14%)
RARE : 46.40 (+2.81%)
FULC : 2.99 (-0.66%)
ANIP : 55.10 (-1.06%)
IONS' Rare Neurology Disorder Candidate Gets FDA's Fast Track Tag

Ionis Pharmaceuticals, Inc. IONS announced that the FDA has granted a Fast Track designation to its investigational RNA-targeted therapy zilganersen for treating Alexander disease (AxD), an ultra-rare...

KRYS : 178.10 (+0.14%)
FULC : 2.99 (-0.66%)
IONS : 35.40 (+4.89%)
ANIP : 55.10 (-1.06%)
Here's Why Investors Should Consider Buying Corcept Stock Now

Corcept Therapeutics’ CORT sole-marketed drug, Korlym (mifepristone), which is approved for treating Cushing's syndrome, has been performing well. The drug has been witnessing strong demand in the past...

CORT : 56.09 (+3.29%)
KRYS : 178.10 (+0.14%)
ANIP : 55.10 (-1.06%)
BVS : 11.41 (-1.55%)
SAVA Stock Down on Settling Misleading Alzheimer's Study Data Claims

Cassava Sciences SAVA has agreed to pay a $40 million fine to settle charges from the U.S. Securities and Exchange Commission (SEC) over allegedly misleading statements about the results of its 2020 mid-stage...

KRYS : 178.10 (+0.14%)
FULC : 2.99 (-0.66%)
ANIP : 55.10 (-1.06%)
SAVA : 26.05 (-6.96%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States.

See More

Key Turning Points

3rd Resistance Point 190.01
2nd Resistance Point 185.85
1st Resistance Point 181.98
Last Price 178.10
1st Support Level 173.94
2nd Support Level 169.78
3rd Support Level 165.90

See More

52-Week High 219.34
Last Price 178.10
Fibonacci 61.8% 173.37
Fibonacci 50% 159.17
Fibonacci 38.2% 144.97
52-Week Low 99.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar